Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

President Donald Trump on Friday announced a deal with pharmaceutical company Merck and its U.S. subsidiary, EMD Serono, to ...

Government agreement with IVF drug manufacturer drops price in exchange for tariff reductions, expedited FDA approval ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression ...

As a newly christened manufacturing facility comes online in one part of Ireland, Merck KGaA plans to turn out the lights at ...

EMD Serono also entered an agreement with the U.S. Secretary of Commerce to exclude its pharmaceutical products and ...

Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...

ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and con ...